B-ALL
Clinical trials for B-ALL explained in plain language.
Never miss a new study
Get alerted when new B-ALL trials appear
Sign up with your email to follow new studies for B-ALL, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug duo targets Hard-to-Treat blood cancers
Disease control CompletedThis early-stage study tested a combination of two drugs, acalabrutinib and ACP-319, in 40 people with B-cell cancers such as non-Hodgkin lymphoma, multiple myeloma, and B-cell acute lymphoblastic leukemia. The goal was to check the safety and effectiveness of the drug pair. Part…
Matched conditions: B-ALL
Phase: PHASE1, PHASE2 • Sponsor: Acerta Pharma BV • Aim: Disease control
Last updated May 17, 2026 04:43 UTC
-
Engineered immune cells take aim at Hard-to-Treat blood cancers
Disease control CompletedThis study tested whether a new type of immune cell therapy, called CD22 CAR T cells, could be made from the blood of adults with certain blood cancers (leukemia and lymphoma) that had come back or not responded to treatment. The main goals were to see if the cells could be succe…
Matched conditions: B-ALL
Phase: PHASE1 • Sponsor: Matthew Frank • Aim: Disease control
Last updated May 17, 2026 04:43 UTC
-
New CAR-T therapy shows promise in tough leukemia
Disease control CompletedThis early-phase study tested a new immune cell therapy called ThisCART19A in 10 adults with B-cell leukemia that had come back or stopped responding to standard treatments. The main goal was to check safety and find the right dose. Researchers also looked at how well the therapy…
Matched conditions: B-ALL
Phase: PHASE1 • Sponsor: Zhejiang University • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
Engineered immune cells show promise against tough childhood cancers
Disease control CompletedThis study tested a new treatment for children and young adults (ages 1-39) with B-cell leukemia or lymphoma that did not respond to standard therapy. The treatment involved taking a patient's own white blood cells, modifying them in a lab to target the CD22 protein on cancer cel…
Matched conditions: B-ALL
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 14, 2026 12:03 UTC